DeCure for Supratentorial primitive neuroectodermal tumor
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for supratentorial primitive neuroectodermal tumor — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSupratentorial primitive neuroectodermal tumor maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for supratentorial primitive neuroectodermal tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dicer 1, ribonuclease III (DICER1) — DICER1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7XW2 · 3.04 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2009 case report describes a primitive neuroectodermal tumour (PNET) in the orbit of a young girl, noting that the tumour expresses the MIC-2 gene (CD99) and appears least aggressive after complete tumour resection. A 2010 case report of Ewing’s sarcoma of the larynx states that most peripheral PNETs (pPNETs) occur in the thoracopulmonary region, pelvis, abdomen, and extremities, with few cases in the head and neck, and that treatment is not well defined. A 2016 retrospective review of 16 patients with pPNETs found the tumours presented as large solid masses with aggressive extension into neighbouring tissue; 11 of 16 showed necrosis, and 5 of 16 showed haemorrhage. The review concluded that pPNET should be a differential diagnosis for large, ill-defined solid masses with aggressive extension and significant enhancement.
A 2011 review states that PNET is a malignant tumour most often affecting children and adolescents, that its incidence has risen, and that it has a low early diagnosis rate and poor treatment effect. The same review claims that progress has been made in diagnosis (RT-PCR, FISH, MRI, PET-CT) and treatment (targeted therapy, multidisciplinary integrated treatment), but provides no survival data, response rates, or sample sizes to support this claim. No abstract reports any clinical trial results, response rates, or survival outcomes for any drug in supratentorial PNET specifically.
What is still missing are prospective clinical trials with survival and response endpoints for any drug in supratentorial PNET, adequate patient stratification by molecular subtype, and dedicated funding for a disease where treatment remains poorly defined.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Indian Journal of Ophthalmology · 2009 · 15 citations · open access
Primary primitive neuroectodermal tumor of the orbit
AbstractPrimitive neuroectodermal tumor (PNET) is a small round cell malignant tumor of neuroectodermal origin. Most of the PNETs occur in the central nervous system (CNS). PNETs recognized outside of CNS are diagnosed as peripheral PNET (pPNET). This tumor which expresses MIC-2 gene (CD99) seems to be least aggressive after complete tumor resection. We describe a rare case of PNET in a young girl.
Journal of Computer Assisted Tomography · 2016 · 0 citations
Computed Tomography and Magnetic Resonance Imaging Characteristics of Peripheral Primitive Neuroectodermal Tumor
AbstractPURPOSE: The aim of this study was to analyze the radiological features of peripheral primitive neuroectodermal tumor (pPNET). MATERIALS AND METHODS: The radiological and clinical findings for 16 patients with pPNETs were retrospectively reviewed. The 16 tumors were classified into 4 groups (meninges group, n = 4; spine group, n = 3; bone group, n = 5; soft-tissue group, n = 4), and clinical data, size, and common and unique CT/MRI characteristics were assessed. RESULTS: Peripheral primitive neuroectodermal tumors presented as large solid masses with aggressive extension into the neighboring tissue. Most tumors (11/16) presented with necrosis, and 5 of the 16 cases showed signs of hemorrhage. The "dural tail sign" was observed in the meninges and spine groups. The pPNETs of bone demonstrated bony destruction with spiculated periosteal reaction, and small nourishing vessels were found in tumors in the soft-tissue group. CONCLUSIONS: Peripheral primitive neuroectodermal tumor should be suggested as an important differential diagnosis when the tumor presents as a large, ill-defined solid mass with aggressive extension and significant enhancement.
The Internet Journal of Head and Neck Surgery · 2010 · 0 citations
Ewing’s sarcoma of larynx: Report of a rare case with review of literature
AbstractPrimitive neuroectodermal tumors (PNETs) are a group of highly malignant tumors composed of small round cells of neuroectodermal origin that affect soft tissue and bone. Most peripheral primitive neuroectodermal tumors (pPNETs) manifest in the thoracopulmonary region (Askin tumor), pelvis, abdomen, and extremities and reveal a paucity of cases in the head and neck. The treatment of these is also not well defined. Here, we present a case report with aim of organ preservation.
Diagnosis and treatment of primitive neuroectodermal tumor
AbstractPrimitive neuroectodermal tumor (PNET) is a kind of malignant tumor, which most often affects children and adolescents. The incidence of PNET has risen recently. PNET has low early diagnosis rate and poor treatment effect. With the application of RT-PCR and FISH in pathological diagnosis, and MRI and PET-CT in imageological diagnosis, as well as the implementation of target treatment and multidisciplinary integrated treatment concept in the treatment, the pathogenesis, diagnosis technology and treatment means of of PNET have made remarkable progress.
Key words:
Neuroectodermal tumors, primitive; Diagnosis; Therapeutics
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
